Combined F-18 NaF and F-18 FDG PET/CT for Evaluation of Malignancy

Stanford University

Status: Completed

Conditions: Neoplasms

Study type: Observational

Funder types: Other

Identifiers

NCT00725387

SU-07232008-1266 (Other Identifier)

VAR0024

98043 (Other Identifier)

Details and patient eligibility

About

Fluorine-18 Fluorodeoxyglucose (F-18 FDG) PET/CT is established as a powerful imaging tool for cancer detection and monitoring response to therapy. Sodium Fluorine-18 (F-18) was used in the 1970s for bone scanning and can be used as a skeletal tracer in current PET/CT scanners. The combined administration of F-18 and F-18 FDG in a single PET/CT scan for cancer detection was not attempted to date. We hope to learn what is the best approach for detection of cancer and thus to improve cancer treatment.

Enrollment: 214 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients older than 18-year-old, diagnosed with cancer
• Patients must understand and voluntarily sign an Informed Consent form after the contents have been fully explained to them

Exclusion criteria

• Patients who cannot complete a PET/CT scan
• Pregnant women
• Healthy volunteers
• Patients participating in other research studies

The subjects will not be paid to participate in this protocol. No costs will be charged to the subjects.